Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Study sponsor: Kyntra Bio
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-06-11Actual
Enrollment · participants284Actual
Source updated2024-11-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.